

Product Code: 0208

HLA-B*57 Plus Box 1.0 Typing Kit

In vitro diagnostics disposal

Instructions Manual



DESENVOLVIMENTO E PRODUÇÃO
DE TESTES DE DIAGNÓSTICO

Version 1.4; May 2010.

Table of contents

Presentation	3
Product changes and improvements.....	3
Quality Control.....	4
Cell line validation sheet.....	4
HLA-B*57 Plus Box 1.0 Typing Kit components.....	5
PCR amplification protocol.....	6
Reagents	6
DNA Extraction.....	6
PCR amplification.....	6
PCR cycling parameters.....	7
Gel Electrophoresis protocol	8
Preparing 2% agarose gel	8
Gel Electrophoresis.....	8
HLA-B*57 Plus Box 1.0 plate	9
HLA-B*57 Plus Box 1.0 plate identification.....	9
Results interpretation sheet.....	10
Results interpretation table	10
Troubleshooting Guide.....	11
Warnings and precautions	12
Technical Guide.....	13
Guarantee.....	14
Warranty	15
Declaration of Conformity	16
Material safety data sheet (MSDS).....	17
References	20

Presentation

Some HLA-B*57 subtypes are associated with the rate of illness progressions in HIV-1 infected patients, particularly B*5701 allele in Caucasians and B*5703 allele in Africans populations. The presence of these alleles is strongly associated with hypersensitivity related with ABACAVIR administration/treatment.

HLA-B*57 is also related with HCV infection and *psoriasis* susceptibility.

This kit contains typing plates with dried primer mix and PCR Master Mix for medium resolution typing of HLA-B*57 gene.

Product Changes and Improvements

The HLA-B*57 Plus Box specificity and interpretation tables are constantly updated, to include new HLA class I alleles described. This product can also be improved in order to increase the yield of the specific PCR product.

The primers exchanged, added or modified, compared to the previous lot, are detailed in the table below.

Tube	primers	motivation
N/A		

Quality Control

The following 3 DNA samples from the *13th International Histocompatibility Workshop SSOP Panel* were used to verify the kit primers mixes specificity.

Workshop Name	Designation
IHW 09052	DBB
IHW 09273	LADA
IHW 09398	FH18

No false positive or negative amplifications were obtained.

The negative control tube can detect cross-contamination with PCR products.

Cell line validation sheet

HLA-B*57 plus resolution SSP typing kit					
Cell line		Cell Typing			HLA-B*57 Positive well no.
		HLA-A*	HLA-B*	HLA-Cw*	
9273	LADA	0201:8001	0702:5703	0701:0802	1a, 1b, 1c, 1e, 1g
9052	DBB	0201	5701	0602	1a, 1b, 1c, 1d, 1g
9398	FH18	7401:3601	5301:5703	0401:0701	1a, 1b, 1c, 1e, 1g

HLA-B*57 Plus Box 1.0 Typing Kit Components

- **HLA-B*57 Plus Box typing plates⁺** (48 typing)
16 plates (3 samples each) (Store at -30 to -15 °C)
- **PCR Master Mix (With Taq DNA Polymerase)**
16 X 96 µl (Store at -30 to -15°C)
- **Plate sealers**
48 sealer caps
- **Instructions Manual**
1 Instructions manual

⁺ With dried specific primers pairs (6 specific primer pairs; 1 negative control and 1 positive control).

PCR Master Mix Components

Nucleotides

Final concentration of each dNTP: 600 µM

PCR Buffer

Final concentration: 3,3x NH₄ Buffer; 2,0 mM MgCl₂ and 0,4 U/µl Taq DNA polymerase, pH 8.3.

Glycerol

Final concentration: 16,6%

Cresol Red

Final concentration: 300µg/ml

PCR amplification protocol

Reagents

- DNA Sample (100-200 ng/ μ l)
- PCR Master Mix
- ddH_2O (not supplied)

DNA Extraction

For SSP typing highly pure DNA is needed. We recommend isolation of DNA using any extraction kit with CE marking, which guarantees an OD ratio 260/280 higher than 1.6 and a DNA concentration between 100ng – 200ng/ μ l.

Alternatively, the DNA can be extracted using trimethylammonium-bromide salts (DTAB/CTAB) or by salting out, dissolving it in TE Buffer. The same OD and concentration values should be assured.

DO NOT USE HEPARINISED BLOOD WITH THIS METHOD

PCR Amplification

1. Spin briefly the DNA and Master Mix tubes.
2. Add:
 - **31 μ l of PCR Master Mix,**
 - **52 μ l of ddH_2O**to a 0,7 ml or 1,5 ml tube.
3. Vortex the tube vigorously for 15s.
4. Load **10 μ l** of the mix into the negative control well.
5. Add **7 μ l** of **DNA sample** (conc. 100-200 ng / μ l) to the mix tube.
6. Vortex the tube vigorously for 15s.
7. Load **10 μ l** of the mix into each tube of the plate (**6 primers pairs and 1 positive control**).

8. Repeat the previous steps for other DNA sample to complete the HLA-B*57 PLUS typing plate.
9. Close the typing strip with a strip cap and put it in a 96 well thermo cycler.

PCR Cycling Parameters

Step	Temperature	time	Cycle
Denaturation	96 °C	1 min	1
Denaturation	96 °C	25 sec	5
Annealing	70 °C	45 sec	
Extension	72 °C	30 sec	
Denaturation	96 °C	25 sec	21
Annealing	65 °C	45 sec	
Extension	72 °C	30 sec	
Denaturation	96 °C	25 sec	4
Annealing	55 °C	1 min	
Extension	72 °C	2 min	
Extension	72 °C	10 min	1
Keep (optional)	4 °C	Infinite	1

10. Keep the plate at 2-8 °C after the PCR have finished.
11. Detect the PCR products with 2% agarose gel electrophoresis.

Gel Electrophoresis protocol

PREPARING 2% AGAROSE GEL


1. Dissolve **4 grams** of electrophoresis **grade agarose** powder in **200 ml** of **1X TAE buffer**.
2. Melt the agarose powder completely in a microwave oven.
3. Cool the heated agarose gel to ~ **50°C**.
4. Add at least 10 µl of **ethidium bromide⁺⁺** (10 mg/ml) or **Sybr SafeTM** (100000 x concentrate) to the heated agarose. Stir until it is thoroughly incorporated.
5. On a balanced surface, set up a gel plate with **96 wells**.
6. Cast a **5mm** thick gel on the plate.
7. Allow the gel to settle.

⁺⁺**Caution**, this reagent is a strong mutagenic agent (read carefully its MSDS before using it).

GEL ELECTROPHORESIS

1. Submerge the gel in 1X TAE buffer in a gel box.
2. Gently remove the caps to avoid splashing of PCR products.
3. Load 10 µl into each well on the gel.
4. Connect the electric leads and turn on the power supply (115V).
Electrophoresis for ~ 20 minutes, or until 2/3 of the lane.
5. Transfer the gel onto a UV transilluminator, document the result by photography.
Use the **result interpretation sheet** to interpret results.

HLA-B*57 Plus Box 1.0 plate



* Numbers may differ from plate to plate:

The no 1 could be 4, 7, 10

The no 2 could be 5, 8, 11

The no 3 could be 6, 9, 12

HLA-B*57 Plus Box 1.0 Plate Identification

Position	HLA-B 57
1a	5701-14
1b	5701-14 except 5708; 5710; 5712
1c	5701-14 except 5705; 5706; 5711
1d	5701; 5706; 5708; 5710; 5711; 5714
1e	5703 and 5707
1f	5714
1g	Positive control
1h	Negative control

Results Interpretation sheet

Position			HLA-B 57	Specific band	Control band**
1a	2a	3a	5701-14	380	790
1b	2b	3b	5701-14 except 5708; 5710; 5712	225	790
1c	2c	3c	5701-14 except 5705; 5706; 5711	165	790
1d	2d	3d	5701; 5706; 5708; 5710; 5711; 5714	165	790
1e	2e	2e	5703 and 5707	155	790
1f	2f	2f	5714	185	790
1g	2g	2g	Positive control	790	—
1h	2h	2h	Negative control	—	—
DNA 1	DNA 2	DNA 3			

**Control primer pares match with non-allelic sequences. The internal positive control primer pairs amplify segments of the HLA-DRB1 gene, 790 base pair fragment.

In the presence of the specific band amplification the control band intensity often decreases.

The PCR reaction is only valid in the presence of control band or, in some cases, in the presence of the specific band.

In the absence of the control band, please repeat the typing.

Results Interpretation Table

Well No.	1a	1b	1c	1d	1e	1f
Associated with disease						
Treatment and clinical symptoms (HLA-B*5701) ⁵⁻¹⁴	+	+	+	+		
No association (HLA-B*5706; 5711) ⁵⁻¹⁴	+		+	+		
No association (HLA-B*5708; 5710) ⁵⁻¹⁴	+	+		+		
No association (HLA-B*5714) ⁵⁻¹⁴	+	+	+	+		+
Association in Africans, No association in Caucasoid (HLA-B*5703) ^{14, 15}	+	+	+		+	

Troubleshooting Guide

PROBLEMS	POSSIBLE CAUSES	SUGGESTIONS
The control and specific bands are weak.	Concentration of DNA sample is too low.	Check DNA quality and concentration
		Re-extract the DNA sample or try not add water into the PCR Mix
		Repeat typing with a good quality DNA sample
	DNA polymerase inhibitors in the DNA sample	Re-purify the sample DNA Repeat typing with a good quality DNA sample
Missing internal control bands in one or several lanes.	DNA polymerase inhibitors in the DNA sample.	Re-purify the sample DNA Repeat typing with a good quality DNA sample
	Dried PCR amplification products	Check the plate sealing Repeat the typing using a PCR MicroMat and/or overlay the PCR reaction mix with mineral oil
False negative of a specific band while the internal control appears normal	Degradation of DNA sample	Re-extract the DNA sample with fresh material Repeat typing with a good quality DNA sample
More than two specific alleles are detected/ Ambiguous results	Excess of template DNA	Check DNA quality and concentration Dissolve the DNA sample in ddH_2O in order to have the proper concentration Repeat typing with a good quality DNA sample
	Contamination with previously amplified PCR products or with other DNA samples during the DNA extraction or PCR preparation steps	Clean the working area Work in separated pre-PCR and post-PCR rooms Keep different lab coats in pre-PCR and post-PCR rooms Change protective gloves frequently Repeat typing with a good quality DNA sample
Blurred bands	Degradation of DNA sample	Re-extract the DNA sample with fresh material Repeat typing with a good quality DNA sample
	Excess of template DNA	Check DNA quality and concentration Dissolve the DNA sample in ddH_2O in order to have the proper concentration Repeat typing with a good quality DNA sample
	Electrophoresis Buffer Problems: wrong buffer or older buffer	Use a fresh recommended buffer

Precautions and Warnings

PCR amplification allows the amplification of small quantities of sample DNA in an exponential way. However, this is also true for foreign DNA, which can contaminate our PCR method. Consequently, special laboratory practices are necessary in order to avoid false positive amplifications. Below is listed Genebox recommendations to circumvent contaminations:

- Work in separated pre-PCR and post-PCR rooms.
- Laboratory workflow must be unidirectional, from pre-PCR to post-PCR area.
- Specific equipment for each working area must be used (sample preparation, preamplification, amplification and postamplification).
- All equipment used in post-PCR should not leave this area.
- Use dedicated micropipettes, gloves and lab coats in each area.
- Use non talcum powder gloves (since talcum could inhibit the PCR reaction).
- Use filter tips in order to avoid cross contamination.
- Check regularly micropipettes, in order to ensure that they are accurate within 5 % of fixed volume.
- Use different micropipettes depending on the volume we wish to load.
- Check regularly thermocyclers, in order to ensure that they are accurate within 1% of fixed temperature.
- Open and close reagent vials carefully. After use, close vials and store at indicated temperatures.
- Do not use a kit after its expiration date.
- packaging material included within the kit is resistant to the indicated storage conditions. Storage at different conditions can cause breakage of the material, and possible contamination of the kit reagents.
- plastic material included within the kit is resistant under normal conditions of use. Use of plastic material in extreme conditions may cause its breakage, and therefore, the impossibility to use the kit.
- check suitability of DNA quantity and quality before use the kit.

General instructions for laboratory safety:

- do not eat, drink or smoke in laboratory work areas
- wear disposable gloves
- wear clean lab coats and eye protection
- wash hands thoroughly after handling specimens and test reagents
- clean the working area before and after kit handling.
- do not pipette by mouth.

Technical Guide

1. DNA Quality and Concentration

For optimal results with the HLA-B*57 Plus Box 1.0 Typing Kit™ the quality of DNA is critical. Good quality DNA means an OD ratio 260/280 higher than 1.6 and the major portion of DNA should run higher than 9.4 kb on an agarose gel. Different quality and concentration values require DNA re-extraction.

The quantity of DNA should be 100ng – 200 ng/μl. Excess of DNA can cause unspecific amplification.

We recommend any DNA extraction kit which has CE marking, in order to obtain this highly DNA purity

2. Taq Polymerase

HLA-B*57 Plus 1.0 Typing Kit™ kits have been intensively tested with the Taq DNA Reagente 5 (Reagente 5, Lisboa, Portugal).

3. PCR Master Mix

For optimal results with the HLA-B*57 Plus Box 1.0 Typing Kit™ it should only be used the master mix supplied.

4. Amplification Procedure

At the end of PCR, examine the degree of evaporation and condensation of PCR reaction mixture. If there is more than 20% volume loss do not validate the results. In order to prevent this you should overlay the PCR reaction mixture with mineral oil or use a MicroMat. It is also a good practice to maintain QC records on the heating lid.

If the temperature of the heating lid is not high enough, it will cause condensation problems on the lid.

5. Thermal Cycler

We recommend the use of any thermocycler with the following characteristics:

- heating rate up to 2.5°C/sec; cooling rate up to 1.5°C/sec; temperature range 4-100°C; temperature uniformity ±0.5°C; heated lid up to 100°C.

6. Expiring Date

As specified in the package labels

**If your problems persist, do not hesitate to contact our
technical support**

+351 231 410 946

Guarantee

geneBOX - R&D Diagnostic Tests guarantees that the primers in HLA-B*57 Plus Box typing kit have the specificities given in the Results Interpretations Sheet/Tables of the product insert.

1. Typing plate

When stored at -20°C, the dried primers are stable for 24 months from the date of manufacture (see lot validity in the package).

When stored at 4°C, the dried primers are stable for 19 months from the date of manufacture (see lot validity in the package).

At room temperature, the dried primers are stable for 3 weeks from the date of the reception.

When the sealer is removed the dried primers shall be stable for 2 days, maximum, in dried conditions.

2. PCR Master Mix

When stored at -20°C, the PCR Master Mix is stable for 18 months from the date of manufacture (see lot validity in the package).

When stored at 4°C, the Master mix is stable for 15 days from the date of the reception.

At room temperature, the master mix shall be stable for 3 days from the date of the reception.

The master mix should not be left or stored with the cap open.

3. DNA

Using extracted DNA from salting out or any kit procedure the samples could be stored at 4°C or -20°C.

The DNA samples stored in dH₂O are stable for 4 weeks (at 4°C) or 24 months (at -20°C).

The DNA samples stored in buffer are stable for 12 months (at 4°C) or 5 years (at -20°C).

Warranty

geneBOX - R&D Diagnostic Tests warrants its products to the client against defects in materials and contents under normal application. The company products under this warranty shall be replaced, at no charge, to the damaged client.

This warranty applies only to products that have been handled and stored in accordance with its recommendations/specifications.

The claims must be posted directly to geneBOX in writing and must be accompanied by a copy of the purchaser's invoice.

This product may not be reformulated, repacked or resold in any form without geneBOX - R&D Diagnostic Tests consent.

Declaration of conformity

Product Name: HLA-B*57 Plus Box

Product Number: GB.02.08

Intended use: HLA-B*57 medium resolution histocompatibility testing.

Manufacturer: geneBOX - R&D Diagnostic Tests,
Biocant – centro de inovação em biotecnologia
núcleo 4, lote 3
3060-197 Cantanhede,
Portugal

We, geneBOX - R&D Diagnostic Tests, hereby declare that this product, to which this declaration of conformity relates, is in conformity with the following standards and other normative documents ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices as transposed into the national laws of the Member States of the European Union.

The technical file of the product is maintained at geneBOX - R&D Diagnostic Tests, Biocant Park, Parque tecnológico de Cantanhede, 3060-197 Cantanhede, Portugal.



Sandra Balseiro
Technical Director

Material Safety Data Sheet (MSDS) (1/3)

geneBOX - R&D Diagnostic Tests™ PCR-SSP Kits

geneBOX™ PCR-SSP typing products

This Material Safety Data Sheet (MSDS) applies to all geneBOX - R&D Diagnostic Tests SSP™ typing kits

1. Chemical products and company identification

Date of Issue:	May 2010
Product group:	geneBOX™ PCR-SSP Typing Products
Manufacturer:	geneBOX - R&D Diagnostic Tests, biocant – centro de inovação em biotecnologia núcleo 4, lote 3 3060-197 cantanhede, portugal
tel/fax:	+351 231 410 946/ +351 231 410 947
e-mail:	info@genebox.com

2. Composition and reagents information

Component	Chemical	Common Name
Plate	Deoxyribonucleic acid Cresol Red	Oligonucleotide
PCR Master Mix	Deoxyribonucleotides NH ₄ Buffer Magnesium chloride Cresol Red Glycerol	Nucleotides MgCl ₂ Glycerine

3. Physic-chemical properties:

Components	Appearance	Colour	Odour
Plate	dried, in plate wells	Red	none
Master Mix	liquid	Pink/red	none

4. Toxicological information

Chemical	Toxicities
Glycerol	LD50= oral 4090 mg/kg (mouse) LD50= oral 12600 mg/kg (rat) LD50= oral 1480 mg/kg (human)

5. Stability and reactivity

Conditions to avoid: Heat and moisture.

Incompatibilities: Strong oxidizing agents, strong bases.

Material Safety Data Sheet (MSDS) (2/3)

6. Personal protection.

Hand protection: Wear appropriate chemically resistant gloves.

Eye protection: Chemical safety goggles are recommended.

Skin protection: Wear laboratory coat.

7. Handling and storage

Handling: Avoid substance contact.

Storage: Protect from light. Store at temperature indicated on package.

Package Damage: reject damaged components.

8. Hazards

Master Mix Components: may be harmful by **inhalation, ingestion or skin absorption**. May cause eye and skin irritation. Material is irritating to mucous membranes and upper respiratory tract. **Ingestion** of large amounts can cause stomach pains, vomiting or diarrhoea.

9. First aid measures

In case of eye contact: Immediately flush eyes with large amounts of water for at least 15 minutes. Call a physician.

In case of skin contact: Immediately wash skin with soap and large amounts of water. Wash contaminated clothing before re-use.

In case of ingestion: Wash out mouth with water provided person is conscious. Call a physician if needed.

In case of inhalation: remove to fresh air, if not breathing give artificial respiration. If breathing difficult, give oxygen. Call a physician.

10. Fire fighting measures

Extinguishing media: Water, carbon dioxide, dry chemical powder or appropriate foam.

Extinguishing media NOT to use: None are known.

Special exposure hazards: May emit toxic fumes of carbon dioxide, carbon monoxide, nitrogen, phosphorus, hydrogen chloride, and hydrogen gas under fire conditions.

Special fire-fighting equipment: When large amounts of substances are released work only with self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

11. Accidental release measures

Personal Precautions: Avoid substance contact. No further requirements.

Cleaning Method: Clean up affected area. No further requirements.

Material Safety Data Sheet (MSDS) (2/3)

12. Ecological information

No data available.

13. Waste disposal information

Waste disposes in accordance with all applicable regulations (the disposals should be incinerated).

14. Transport information

During transportation the temperature could not exceed 25°C.
Transportation should not exceed 3 days.

15. Other information

The above information is based on our current level of knowledge, but does not purport to be all-inclusive and shall be used only as a guide. *geneBOX - R&D Diagnostic Tests* shall not be held liable for any damage resulting from handling or from contact with the above products.

**If your problems persist, do not hesitate to contact our
technical support**

+351 231 410 946

References

1. Bunce M, O'Neill CM, Barnardo MCNM, Krausa P, Browning MJ, Morris PJ, Welsh KI. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilising sequence-specific primers (PCR-SSP). *Tissue Antigens* 1995; 46: 355-367.
2. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Charron, Dupont B, Erlich HA, Fauchet R, Bach B, Mayr WR, Parham P, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA System, 1996. *Hum Immunol* 1997; 53: 98-128.
3. Nomenclature for factors of the HLA System. Compiled by Steven G. E. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. <http://www.anthonynolan.com/HIG/nomenc.html>
4. Schaffer M, Olerup O. HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. *Tissue Antigens*. 2001; 58: 299-307.
5. Phillips E, Mallal S. Drug hypersensitivity in HIV. *Curr Opin Allergy Clin Immunol*. 2007;7:324-30.
6. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. *AIDS*. 2007;21:2533-4.
7. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet*. 2002;359:727-32.
8. Vilar FJ, Naisbitt DJ, Park BK, Pirmohamed M. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. *J HIV Ther*. 2003;8:42-7.
9. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. *J Antimicrob Chemother*. 2007;59:591-3.
10. Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PRA simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. *Clin Infect Dis*. 2007;44:1503-8.
11. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med*. 2008;358:568-79.
12. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, Chang SC. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. *J Antimicrob Chemother*. 2007;60:599-604.
13. Hughes DA, Vilar FJ, Ward CC, Alfrevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. *Pharmacogenetics*. 2004;14:335-42.
14. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD; CNA30027 Study Team; CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. *Pharmacogenomics*. 2004;5:203-11.
15. Gillespie GM, Stewart-Jones G, Rengasamy J, Beattie T, Bwayo JJ, Plummer FA, Kaul R, McMichael AJ, Easterbrook P, Dong T, Jones EY, Rowland-Jones SL. Strong TCR Conservation and Altered T Cell Cross-Reactivity Characterize a B*57-Restricted Immune Response in HIV-1 Infection. *J Immunol*. 2006 Sep 15;177(6):3893-902.



DESENVOLVIMENTO E PRODUÇÃO
DE TESTES DE DIAGNÓSTICO



0197

biocant – centro de inovação em biotecnologia
núcleo 4, lote 3
3060-197 cantanhede
portugal

tel + 351 231 410 946
fax + 351 231 410 947
e-mail info@genebox.com
www.genebox.com